To see the other types of publications on this topic, follow the link: Rheumatic.
Journal articles on the topic 'Rheumatic'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Rheumatic.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Kostine, Marie, Marie-Elise Truchetet, and Thierry Schaeverbeke. "Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy." Rheumatology 58, Supplement_7 (December 1, 2019): vii68—vii74. http://dx.doi.org/10.1093/rheumatology/kez295.
Full textAbstract:
AbstractCompared with conventional cancer therapies, the spectrum of toxicities observed with checkpoint inhibitors is unique and can affect any organ system. Arthralgia and myalgia were by far the most commonly reported rheumatic immune-related adverse events in clinical trials, and there is now a growing number of case series and reports describing clinical features of de novo rheumatic immune-related adverse events, which will be the focus of this review. Some patients develop genuine classic rheumatic and musculoskeletal diseases, but a number of rheumatic immune-related adverse events mimic rheumatic and musculoskeletal diseases with atypical features, mainly polymyalgia rheumatica, rheumatoid arthritis and myositis, as well as several systemic conditions, including sicca syndrome, vasculitis, sarcoidosis, systemic sclerosis and lupus.
2
Kemeny-Beke, Adam, and Peter Szodoray. "Ocular manifestations of rheumatic diseases." International Ophthalmology 40, no. 2 (October 3, 2019): 503–10. http://dx.doi.org/10.1007/s10792-019-01183-9.
Full textAbstract:
Abstract Purpose Our aim was to summarize key aspects of the pathomechanism and the ocular involvements of rheumatic and systemic autoimmune diseases. Methods Apart from a paper in French (Morax V, Ann Oculist 109:368–370, 1893), all papers referred to in this article were published in English. All the materials were peer-reviewed full-text papers, letters, reviews, or book chapters obtained through a literature search of the PubMed database using the keywords ocular manifestations; pathogenesis; systemic inflammatory rheumatic diseases; rheumatoid arthritis; osteoarthritis; fibromyalgia; systemic lupus erythematosus; seronegative spondyloarthritis; ankylosing spondylitis; reactive arthritis; enteropathic arthritis; psoriatic arthritis; systemic sclerosis; polymyalgia rheumatica and covering all years available. Some statements articulated in this paper reflect the clinical experience of the authors in their tertiary-referral center. Results Ophthalmic disorders are categorized by anatomical subgroups in all rheumatic diseases. The most common ocular manifestations are diverse types of inflammations of different tissues and dry eye disease (DED). Conclusion The eye could be a responsive marker for the onset or aggravation of an immune reactivation in many rheumatic diseases, furthermore, ocular findings can antedate the diagnosis of the underlying rheumatic disease. By recognizing ocular manifestations of systemic rheumatic diseases it might be possible to avoid or at least delay many long term sequelae.
3
Kostine, Marie, Léa Rouxel, Thomas Barnetche, Rémi Veillon, Florent Martin, Caroline Dutriaux, Léa Dousset, et al. "Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study." Annals of the Rheumatic Diseases 77, no. 3 (November 16, 2017): 393–98. http://dx.doi.org/10.1136/annrheumdis-2017-212257.
Full textAbstract:
ObjectivesTo evaluate the prevalence and type of rheumatic immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICIs), as well as the correlation with tumour response.MethodsThis was a single-centre prospective observational study including all cancer patients receiving ICIs. The occurrence of irAEs and tumour response was assessed on a regular basis. Patients who experienced musculoskeletal symptoms were referred to the department of rheumatology for clinical evaluation and management.ResultsFrom September 2015 to May 2017, 524 patients received ICIs and 35 were referred to the department of rheumatology (6.6%). All but one of the rheumatic irAEs occurred with anti-programmed cell death protein 1(PD-1)/PD-1 ligand 1(PD-L1) antibodies, with a median exposure time of 70 days. There were two distinct clinical presentations: (1) inflammatory arthritis (3.8%) mimicking either rheumatoid arthritis (n=7), polymyalgia rheumatica (n=11) or psoriatic arthritis (n=2) and (2) non-inflammatory musculoskeletal conditions (2.8%; n=15). One patient with rheumatoid arthritis was anti-cyclic citrullinated peptide (anti-CCP) positive. Nineteen patients required glucocorticoids, and methotrexate was started in two patients. Non-inflammatory disorders were managed with non-steroidal anti-inflammatory drugs, analgesics and/or physiotherapy. ICI treatment was pursued in all but one patient. Patients with rheumatic irAEs had a higher tumour response rate compared with patients without irAEs (85.7% vs 35.3%; P<0.0001).ConclusionSince ICIs are used with increasing frequency, knowledge of rheumatic irAEs and their management is of major interest. All patients were responsive either to low-to-moderate doses of prednisone or symptomatic therapies and did not require ICI discontinuation. Furthermore, tumour response was significantly higher in patients who experienced rheumatic irAEs.
4
Nacar, N. E., N. B. Karaca, L. Kiliç, S. Kiraz, and E. Ünal. "AB1498 THE BIOPSYCHOSOCIAL-BASED EXERCISE MODEL VIA TELEREHABILITATION IN PATIENTS WITH INFLAMMATORY AND NON-INFLAMMATORY RHEUMATIC DISEASES: A PROSPECTIVE COHORT STUDY DURING THE COVID-19 PANDEMIC." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 1852.2–1853. http://dx.doi.org/10.1136/annrheumdis-2022-eular.5022.
Full textAbstract:
BackgroundDuring the COVID-19 pandemic, the patients with rheumatic disease in the biopsychosocial perspective have been adversely affected by social isolation, uncertainty, and the thought that their chronic disease will worsen and increase in their symptoms. ACR/EULAR (American College of Rheumatology / European League Against Rheumatism) defines recommendations about continuing current pharmacotherapy and the significance of the biopsychosocial approach and exercise for patients with rheumatic diseases during a COVID-19 infection 1, 2.ObjectivesThis study aims to investigate the effectiveness of the biopsychosocial exercise performed by telerehabilitation on biopsychosocial status, general health status, and anxiety-depression levels in the patients with inflammatory and non-inflammatory rheumatic diseases.MethodsFourteen patients with inflammatory rheumatic diseases (rheumatoid arthritis: 4; ankylosing spondylitis: 4; sjogren’s syndrome: 3; polymyalgia rheumatica: 2; and vasculitis: 1) and eight patients with non-inflammatory rheumatic diseases (fibromyalgia: 6; and osteoarthritis: 2) performed a biopsychosocial-based exercise model (named as “Bilişsel Egzersiz Terapi Yaklaşimi”-(BETY) in original; “Cognitive Exercise Therapy Approach” in English) via telerehabilitation continued for three sessions per week for 12 months 3. Outcome measures were Health Assessment Questionnaire (HAQ), Hospital Anxiety and Depression Scale (HADS), and BETY-Biopsychosocial Questionnaire (BETY-BQ) 4. All outcomes were measured baseline and at the 12th month. The Wilcoxon’s test was used for statistical analysis.ResultsAll of the 22 patients were female. The mean age was 57.4 and 55.8 years in the inflammatory and non-inflammatory rheumatic diseases groups respectively, and they had a mean BMI of 25.9 and 25.3 kg/m2. There was no significant difference by time for HAQ score (p = 0.125), HADS anxiety and depression (p = 0.916 and p = 0.663, respectively), and BETY-BQ score (p = 0.753) between the baseline and at the 12th month follow-up in the patients with inflammatory rheumatic diseases. Similarly, in the patients with non-inflammatory rheumatic diseases, there was no significant difference by time for HAQ score (p = 0.546), HADS anxiety and depression (p = 0.343 and p = 0.527, respectively), and BETY-BQ score (p = 0.068) between the baseline and at the 12th month follow-up.ConclusionThis study showed that biopsychosocial-based exercise through real-time telerehabilitation was able to maintain their conditions before pandemic in biopsychosocial status, general health, and anxiety-depression levels on the patients with inflammatory and non-inflammatory rheumatic diseases during COVID-19 pandemic period in one-year follow-up.References[1]England BR, Barber CE, Bergman M, Ranganath VK, Suter LG, Michaud K. Brief Report: adaptation of American College of Rheumatology Rheumatoid Arthritis Disease Activity and functional status measures for telehealth visits. Arthritis Care Res (Hoboken). 2020.[2]Landewé RB, Machado PM, Kroon F, Bijlsma HW, Burmester GR, Carmona L, Combe B, Galli M, Gossec L, Iagnocco A. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis. 2020;79(7):851-8.[3]Kisacik P, Unal E, Akman U, Yapali G, Karabulut E, Akdogan A. Investigating the effects of a multidimensional exercise program on symptoms and antiinflammatory status in female patients with ankylosing spondylitis. Complementary therapies in clinical practice. 2016;22:38-43.[4]Edibe Ü, Gamze A, KARACA NB, KİRAZ S, AKDOĞAN A, KALYONCU U, ERTENLİ Aİ, BİLGEN ŞA, KARADAĞ Ö, ERDEN A. Romatizmali hastalar için bir yaşam kalitesi ölçeğinin geliştirilmesi: madde havuzunun oluşturulmasi. Journal of Exercise Therapy and Rehabilitation. 2017;4(2):67-75.Disclosure of InterestsNone declared
5
Lujano Negrete, A. Y., C. M. Skinner Taylor, L. Pérez Barbosa, F. Hernández, R. A. Rodriguez Chavez, L. G. Espinosa Banuelos, R. Moyeda Martinez, A. Cárdenas, and D. Á. Galarza-Delgado. "AB0842 CESAREAN SECTION IN MEXICAN WOMEN WITH AUTOIMMUNE RHEUMATIC DISEASES." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 1444.2–1445. http://dx.doi.org/10.1136/annrheumdis-2021-eular.3679.
Full textAbstract:
Background:Rheumatic diseases occur among women of childbearing age, adverse events during pregnancy in rheumatic diseases have been frequently reported. Mexico has one of the largest prevalence of cesarean section in women which negatively impacts the product.Objectives:The objective of this study is to describe the frequency of cesarean section in women with autoimmune rheumatic diseases compared to a control group.Methods:We conducted a cross-sectional and retrospective study in patients from the pregnancy and rheumatic diseases clinic, and the Obstetrics department form the University Hospital “Dr. José E. González” in Northeast Mexico. Women with autoimmune rheumatic diseases that gave birth between August 2017 to December 2020 were included. All the data, including the way of birth was retrieved from the clinical files.Results:One hundred and twelve patients were included (56 in the rheumatic disease group and 56 women without rheumatic diseases), two of them suffered miscarriage (one from the rheumatic disease group and 1 from the control group) giving a total of 110 products. The mean age was 29.6 years for the rheumatic patients and 24.6 for the control group. The most frequent rheumatic disease was RA in 22 patients (39.2%), followed by SLE in 13 patients (23.21%).From the 56 pregnancies on the rheumatic disease group more than half ended by cesarean section (n=33, 58.92%) and there were 22 simple vaginal delivery. Table 1. On the control group there were 24 cesarean section procedures and 31 simple vaginal delivery. The indications for cesarean sections are presented in Figure 1. No statistically significant difference was found on cesarean section prevalence between both groups (p=0.389).The most common indication for cesarean section in all patients was previous cesarean procedure. (n=12, 36.36%). There were more pathological fetal cardiotocographic changes (PFCC) as an indication for cesarean section on the rheumatic diseases group (n=11, p 0.002) compared with the control group (n=1).Conclusion:A higher prevalence of cesarean sections was found in women with rheumatic diseases versus women without rheumatic diseases, although this difference was not statistically significant. Studies with a higher sample size are necessary to elucidate the complications and differences between both groups.References:[1]Jara LJ, Cruz-Dominguez MDP, Saavedra MA. Impact of infections in autoimmune rheumatic diseases and pregnancy. Curr Opin Rheumatol. 2019;31(5):546-52.[2]Saavedra MA, Sánchez A, Bustamante R, Miranda-Hernández D, Soliz-Antezana J, Cruz-Domínguez P, et al. [Maternal and fetal outcome in Mexican women with rheumatoid arthritis]. Rev Med Inst Mex Seguro Soc. 2015;53 Suppl 1:S24-9.[3]Smeele HTW, Dolhain R. Current perspectives on fertility, pregnancy and childbirth in patients with Rheumatoid Arthritis. Semin Arthritis Rheum. 2019;49(3s):S32-s5.[4]Sugawara E, Kato M, Fujieda Y, Oku K, Bohgaki T, Yasuda S, et al. Pregnancy outcomes in women with rheumatic diseases: a real-world observational study in Japan. Lupus. 2019;28(12):1407-16.[5]Vinet É, Bernatsky S. Outcomes in Children Born to Women with Rheumatic Diseases. Rheum Dis Clin North Am. 2017;43(2):263-73.Table 1.Demographic charecteristicsDISEASEN (%)AGE, YEARS MEANDURATION OF DISEASE, YEARS MEANCESAREAN SECTIONSIMPLE VAGINAL DELIVERYOTHERSRA22 (39.2%)29.956.7711101 MiscarriageAPS9 (16.98)28.222.7781DM3(5.35%)203.521IA3(5.35%)21.5321SS4 (7.14%)30.254.7531JIA2 (3.57%)361511SLE13 (23.21)31.835.3375TOTAL5629.641509433322RA: Rheumatoid Arthritis, APS: Anti-phospholipid syndrome, DM: Dermatomyositis, IA: Idiopathic arthritis, SS: Sjogren syndrome, JIA: Juvenile idiopathic arthritis, SLE: Systemic Lupus ErythematosusDisclosure of Interests:None declared
6
Afridon, Afridon. "FAKTOR-FAKTOR YANG BERHUBUNGAN DENGAN KEJADIAN REMATIK PADA PENDERITA REMATIK DI KELURAHAN VI SUKU WILAYAH KERJA PUSKESMAS TANAH GARAM KOTA SOLOK." Ensiklopedia Education Review 2, no. 1 (February 25, 2021): 1–10. http://dx.doi.org/10.33559/eer.v2i1.653.
Full textAbstract:
Rheumatic disease is a disease affecting the joints and surrounding structures, consisting of more than 100 types. Rheumatoid Arthritis (RA) is a progressive autoimmune disease with chronic inflammation that attacks the musculoskeletal system but can involve the organs and systems of the body as a whole, characterized by swelling, joint pain and destruction of synovial tissue accompanied by movement disorders followed by premature death. This type of research is analytical, with a cross sectional design, where in this study, the dependent and independent variables will be observed at the same time, this method is expected to be known "Factors Associated with Rheumatic Incidence in Rheumatism Patients in Village VI Ethnic Work Area. Puskesmas Tanah Garam Kota Solok ". Based on the results of research conducted on 40 respondents, it can be concluded that there is a relationship between genetics and the incidence of rheumatism, there is a relationship between age and the incidence of rheumatism, there is a relationship between sex and the incidence of rheumatism, there is a relationship between obesity and the incidence of rheumatism and a relationship between lifestyle and incidence rheumatism in Kelurahan VI Tribe, Tanah Garam Public Health Center, Solok City.
7
Djunarko, Ipang, Nanang Fakhrudin, Arief Nurrochmad, and Subagus Wahyuono. "Identification Bioactive Compound of Ethanol-Water Fraction of Coleus atropurpureus for Anti-rheumatic Rheumatism in CFA-induced Rats." Journal of Pharmaceutical Sciences and Community 19, no. 2 (November 30, 2022): 93–102. http://dx.doi.org/10.24071/jpsc.004746.
Full textAbstract:
Nonsteroidal anti-inflammatory drugs are used for pain and to slow the progression of rheumatoid arthritis. Accordingly, the discovery of rheumatoid arthritis active compounds from the ethanol-water fraction Coleus atropurpureus (EWC) was conducted to characterize the isolated compounds as well as the anti-rheumatic effects of the EWC induced Complete Freund's Adjuvant (CFA). We conducted in vivo study in rats which were randomly divided into 5 groups. Group 1 was only given CFA as a negative control. Group 2 as positive control was orally exposed to diclofenac potassium (9 mg/BW). Three groups were given different EWCs orally as follows: 11.25 mg/BW, 22.5 mg/BW, and 45 mg/BW, respectively. Rheumatism rates were then compared with positive controls using a visual arthritic scoring system. The compounds identified by isolation of the EWC of Coleus atropurpureus predicted forskolin. The ethanol-water fraction Coleus atropurpureus did not act as an anti-rheumatic arthritis agent in CFA-induced rats.
8
Gediz, Fusun, and Senol Kobak. "Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know?" Current Rheumatology Reviews 15, no. 3 (July 31, 2019): 201–8. http://dx.doi.org/10.2174/1573397115666190119094736.
Full textAbstract:
: Immune checkpoint inhibitors are revolutionized drugs for cancer immunotherapy in the last years. The mechanism of action of CPIs including the limitation of the activation of Tcells, and thus enhancing the self-immune response against tumour cells. Checkpointinhibitors( CPIs) may dysregulate the immune system, resulting in some toxicities. These toxicities or side effects are called Immune-related Adverse Events (IRAEs) that can potentially affect any organ and tissue. Rheumatic diseases due to checkpoint inhibitors are also reported in the literature. The spectrum of rheumatic manifestations are quite wide; the most common are arthralgia/arthritis, myalgia/myositis, polimyalgia rheumatica, lupus, rheumatoid arthritis, Sjögren’s syndrome. At the same time, these drugs can also cause an exacerbation of known rheumatologic disease. Treatment approaches for developing rheumatic findings due to checkpoint inhibitors should be multidisciplinary. There should be a close relationship between oncologists who follow-up these patients and rheumatologists. The rheumatic manifestations should be defined and treated early. In general, the musculoskeletal side effects are transient and may regress after stopping CPIs. The most commonly used medications are corticosteroids. Immunosuppressive drugs (HQ, MTX, anti-TNF-alpha, anti-IL-6) should be preferred when treatment is unresponsive or as steroid-sparing agents. : The aim of this review was to evaluate the checkpoint inhibitors-related rheumatologic findings and therapeutic strategies in light of recent literature data.
9
Jatwani, K., K. Chugh, I. Tan, and S. Jatwani. "FRI0520 HOSPITALIZATIONS FOR HEMATOLOGICAL MALIGNANCIES WITH RHEUMATIC DISEASES: A NATIONAL INPATIENT SAMPLE ANALYSIS OF TEN YEARS (2005-2014)." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 859–60. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3002.
Full textAbstract:
Background:Several rheumatic conditions have been associated with increased risk of malignancies, especially hematopoietic and lymphoproliferative malignancies. Rheumatoid arthritis has been associated with a relative risk of 1.5-4 for the development of hematological malignancies (HM)1. A variety of immunosuppressive and immunomodulatory medications have also been linked to increased risk of HM2. Moreover, with advances in the field of biologic agents being used in the treatment of rheumatic diseases (RD), the landscape keeps changing. To our knowledge, data on general trends of HM as well as in RD is limited.Objectives:Our study aimed to determine the trends of hospitalizations for HM in patients with RD.Methods:We identified admissions with HM with underlying RD (including rheumatoid arthritis systemic lupus erythematosus, inflammatory myositis, scleroderma, polymyalgia rheumatica, and connective tissue disease) from the NIS database using International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes from years 2005 to 2014. The primary outcome was the trends in hospitalizations for HM. We studied the yearly trends and the types of HM among hospitalizations with or without RD.Results:906,556 weighted hospitalizations were estimated for HM, and amongst those, 17,675 had underlying RD. The demographic analysis suggested that the average age of hospitalizations with HM and RD was higher, were more often females, and a higher number of comorbidities (Table 1). The average number of admissions remained stable for HM with and without HM, as described in Graph 1. There was a significant difference in the frequency of various subtypes in patients with and without RD (Graph 2). Non-Hodgkin’s Lymphoma was the most common subtype in HM without and with RD (35.8% and 47.14%).Table 1.Baseline Demographics of Hospitalizations for HM with and without RDCharacteristicsHM without RDHM with RDp valueAge (in years ± SD)62.05 ± 0.2367.41 ± 0.29<0.05Gender (%)<0.05 Males55.9933.35 Female44.0166.65Race (%)<0.05 White71.2475.88 Black12.2711.31 Hispanic10.217.62 Asian or Pacific Islander2.662.01 Native American0.430.62 Other3.182.55Charlson Category (%)<0.05 255.073.76 321.8346.93 411.5523.71 55.5412.88 >=66.0112.73Type of Insurance (%)<0.05 Medicare49.4966.35 Medicaid10.936.04 Private35.826.19 Self-Pay3.781.42Conclusion:To our knowledge, this is the first study to analyze trends in HM with RD. There has not been any significant change in the number of hospitalizations for HM from 2005-2014 with or without RD. The most common HM in admissions with RD were Non-Hodgkin’s Lymphomas (NHL) and myeloid leukemias, followed by multiple myeloma. The trends suggest no significant change in subtypes of HM over the study period.Graph 1.Hospitalizations per year for Hematologic Malignancies With Rheumatic Diseases 2005-2014Graph 2.Types Of Hematological Malignancies In Hospitalizations With And Without Rheumatic Diseases (%)References:[1] Thomas E, Brewster DH, Black RJ, et al. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497 –502.[2] Jones M, Symmons D, Finn J, et al. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol 1996;35:738 –45.Disclosure of Interests:None declared
10
Abhishek, Abhishek, Annamaria Iagnocco, J. W. J. Bijlsma, Michael Doherty, and Frédéric Lioté. "Cross-sectional survey of the undergraduate rheumatology curriculum in European medical schools: a EULAR School of Rheumatology initiative." RMD Open 4, no. 2 (September 2018): e000743. http://dx.doi.org/10.1136/rmdopen-2018-000743.
Full textAbstract:
ObjectivesTo survey the undergraduate rheumatic and musculoskeletal diseases (RMDs) curriculum content in a sample of medical schools across Europe.MethodsThe undergraduate musculoskeletal diseases and disability curriculum of University of Nottingham, UK, was used as a template to develop a questionnaire on curriculum content. The questionnaire elicited binary (yes/no) responses and included the option to provide additional information as free text. The survey was mailed to members of the European League Against Rheumatism (EULAR) School of Rheumatology (Undergraduate Classroom) and to EULAR Standing Committee on Education and Training members in January 2017, with a reminder in February 2017.ResultsResponses were received from 21 schools belonging to 11 countries. Assessment of gait, hyperalgesic tender site response and hypermobility were not included in many curricula. Similarly, interpretation of investigations undertaken on synovial fluid was taught in only 16 schools. While disease-modifying anti-rheumatic drugs and biological agents, and urate-lowering treatment were included in the curricula of 20 and 21 institutions, respectively, only curricula from 18 schools included core non-pharmacological interventions. Osteoarthritis, gout, rheumatoid arthritis, spondyloarthropathy, polymyalgia rheumatica and lupus were included in the curriculum of all institutions. However, common RMDs such as calcium pyrophosphate deposition, fibromyalgia, giant cell arteritis and bone and joint infection were included in 19 curricula.ConclusionThis survey highlights areas of similarities and differences in undergraduate curricula across Europe. It is hoped that the results of this survey will catalyse the development and agreement of a minimum core European Curriculum for undergraduate education in RMDs.
11
Lenfant, T., L. Calabrese, and C. Calabrese. "FRI0494 RHEUMATIC IMMUNE RELATED ADVERSE EVENTS OF CHECKPOINT INHIBITORS: A RETROSPECTIVE REVIEW OF 70 PATIENTS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 845.2–846. http://dx.doi.org/10.1136/annrheumdis-2020-eular.772.
Full textAbstract:
Background:Immune Checkpoint inhibitors (ICI) have revolutionized cancer therapy by achieving remarkable survival benefits however, at the cost of a myriad of immune-related adverse events (irAEs)[1]. Rheumatic irAE can develop in 5-10% of patients although the true incidence is unknown given the lack of prospective studies [2]. Symptoms are heterogenous and probably underreported with few data available about their management and outcome [3].Objectives:To describe the clinical, biological, and radiological features of the largest cohort of rheumatic irAEs from ICI along with their therapeutic management, outcome and follow-up in real-world practice.Methods:A referral process for emergent rheumatic irAEs was initiated in February 2016 between the oncology and rheumatology departments at the Cleveland Clinic Foundation. All patients were evaluated by authors CC and/or LHC. Patients’ characteristics were retrospectively collected from medical charts after IRB approval.Results:70 patients referred for one or more rheumatic irAEs between February 2016 and January 2020 were included. 66% were male, median age was 60.8 years. Among them, 24 (34%) had pre-existing rheumatic complaints. Melanoma was the most frequent malignancy (56%). ICI therapy included anti-CTLA4 (40%), anti-PD1/L1 (79%), and dual therapy ipilimumab/nivolumab (41%). Rheumatic irAE occurred in a median 4 months after ICI initiation, with phenotypes including inflammatory arthritis (32 patients), sicca-like symptoms (12), polymyalgia rheumatica-like (7), and myositis (2). Oral, intravenous or intraarticular glucocorticoids (GC) were administered to 54 patients (77%). Of these 54 patients, 22 (41%) required long term GC, 19 had bone density scan and 15 received pneumocystis (PJP) prophylaxis. One PJP case, 1 osteoporotic fracture and 2 avascular necrosis cases were reported. 16 patients received conventional DMARDS (23%) and 9 received biologics (13%). ICI therapy was held for rheumatic irAE in 31% of cases and for another systemic irAE in 29%. Median follow-up was 13.6 months, at end of follow-up 51 patients were still on treatment for rheumatic irAE and 41% of them were still symptomatic despite ongoing treatment.Conclusion:Rheumatic irAEs are heterogeneous and often chronic requiring prolonged immunomodulatory therapy. Prospective studies are required to define optimal management of rheumatic irAEs that maintain long-term oncologic outcomes.References:[1]Suarez-Almazor ME, Kim ST, Abdel-Wahab N, Diab A. Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer. Arthritis Rheumatol 2017;69:687–99.https://doi.org/10.1002/art.40043.[2]Abdel-Wahab N, Suarez-Almazor ME. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy. Rheumatol (United Kingdom) 2019;58:vii40–8.https://doi.org/10.1093/rheumatology/kez297.[3]Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis 2018;77:393–8.https://doi.org/10.1136/annrheumdis-2017-212257.Disclosure of Interests:Tiphaine Lenfant: None declared, Leonard Calabrese Consultant of: AbbVie, GSK, Bristol-Myers Squibb, Genentech, Janssen, Novartis, Sanofi, Horizon, Crescendo, and Gilead, Speakers bureau: Sanofi, Horizon, Crescendo, Novartis, Genentech, Janssen, and AbbVie, cassandra calabrese Consultant of: AbbvieGSK, Speakers bureau: Sanofi-Genzyme
12
TM, Ananda Kesavan. "Rheumatic Pneumonia: A Rare Complication of Acute Rheumatic Fever." Indian Journal of Trauma and Emergency Pediatrics 11, no. 3 (2019): 79–81. http://dx.doi.org/10.21088/ijtep.2348.9987.11319.4.
Full text
13
Erizon, Desy Merilla, Afridon Afridon, Mitra Andini, and Aida Adha. "Sosialisasi Penyakit Rematik Terutama Terhadap Pola Makan dan Olahraga pada Penderita Rematik di Kelurahan VI Suku Wilayah Kerja Puskesmas Tanah Garam Kota Solok." Jurnal Pustaka Mitra (Pusat Akses Kajian Mengabdi Terhadap Masyarakat) 2, no. 3 (September 30, 2022): 203–7. http://dx.doi.org/10.55382/jurnalpustakamitra.v2i3.237.
Full textAbstract:
Rheumatoid arthritis (RA) adalah perubahan aoutoimun yang ditandai dengan inflamasi sistemik kronik dan progresif pada sendi terutama di ekstermitas.Penyebab rheumatoid arthritis salah satunya adalah pengaturan pola makanan yang menjadi faktor pemicu arthritis. Pencegahan kekambuhan RAdapat dilakukan dengan Pemantauan aktivitas penyakit menggunakan Disease Activity Score 28 (DAS28) agar mendapat penanganan dini. Selain itu, sebaiknya mengadakan perubahan-perubahan kecil pada pengaturan pola makan juga mengurangi makanan yang dapat mempengaruhi kekambuhan RA. Pengaturan pola makan yang baik sesuai dengan komponen pola makan yaitu dari jenis makanan, jumlah porsi makan, dan frekuensi makan. Di Kota Solok Penderita Rheumatic dari 4 puskesmas yang ada dikota Solok, puskesmas Tanah Garam yang paling banyak masyarakat yang menderita Rheumatic dari Bulan Maret-Mei 2022 yaitu 100 orang. Tujuan dari kegiatan pengabdian kepada masyarakat ini yaitu untuk menambah pengetahuan masyarakat tentang Penyakit Rematik, untuk mengetahui tentang pola makan penderita rematik, mengetahui penyebab tentang kekambuhan rheumatic dan pelaksanaan olah raga untuk penderita rheumatic. Kegiatan pengabdian masyarakat ini dilaksanakan pada tanggal 13 Juni 2022. Peserta berjumlah 8 orang yang terdiri dari 1 orang lansia laki-laki dan 7 orang lansia perempuan. Peserta dapat menjelaskan tentang Pola Hidup dan memperagakan olahraga rheumatic untuk pencegahan rheumatic berulang.
14
Chichasova, N. V. "Differential diagnosis in joint and spine damages." Modern Rheumatology Journal 14, no. 2 (May 30, 2020): 14–19. http://dx.doi.org/10.14412/1996-7012-2020-2-14-19.
Full textAbstract:
The lecture covers main approaches to differential diagnosis in rheumatic diseases. It highlights the key questions that should be answered at the primary examination of the patient. The most important signs that can identify severe, sometimes urgent nonrheumatic diseases are presented. The author describes pain of different patterns and intensity and the most common variants of acute or chronic onset of mono-, oligo-, or polyarthritis. The 2016 European League Against Rheumatism (EULAR) definition of arthralgia suspicious for the development of rheumatoid arthritis is given. The lecture presents the signs indicating the inflammatory nature of back pain in cases of suspected spondyloarthritis (SpA), as well as a two-step diagnostic strategy for axial SpA. Attention is paid to the semiotics of joint damage and extra-articular manifestations in various rheumatic diseases. A brief algorithm for a differential diagnostic search for joint pain is given.
15
Álvarez-Reguera, C., L. Sanchez-Bilbao, S. Fernández López, A. Batlle-López, A. Herrero-Morant, D. Martínez-López, M. Á. González-Gay, and R. Blanco. "AB1320 JAK2 (V617F) MUTATION AND ASSOCIATION TO RHEUMATOLOGICAL DISEASES TREATMENT. STUDY OF 130 PATIENTS FROM A SINGLE UNIVERSITY HOSPITAL." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 1766.2–1767. http://dx.doi.org/10.1136/annrheumdis-2022-eular.4864.
Full textAbstract:
BackgroundJanus Kinases (JAK) can promote cytokine production in immune and hematopoietic cells. The JAK-2 (V617F) mutation is the most frequently detected mutation in myeloproliferative neoplasms (MPN) which include essential thrombocythemia (ET), polycythemia vera (PV), primary myelofibrosis (PMF) and undifferenciated MPN. JAK-2 (V617F) mutation displays a pro-inflammatory phenotype that may be associated to a higher risk of immune mediated diseases (IMID).ObjectivesIn a wide series of JAK2 (V617F) mutation, we assess the presence of a) IMID (rheumatic and non-rheumatic), b) treatment of rheumatic IMID.MethodsWe studied all the patients diagnosed with a positive JAK-2 (V16F) mutation in a single University Hospital from January 2004 to December 2019. JAK-2 (V16F) mutation was detected by using both peripheral blood and bone marrow samples. Associated IMID and treatment of rheumatic IMID were evaluated.ResultsWe included 130 patients (73 men/57 women; mean age, 70.1±14.5 years). All of them were diagnosed of MPN; ET (n=64, 49.2%), PV 46 (35.4%), undifferentiated MPN (n=12, 9.2%) and PMF (n=8, 6.1%). In 10 of these 130 patients (7.7%) a rheumatic IMID was diagnosed: rheumatoid arthritis (RA) (n=4; 40%), polymyalgia rheumatica (PMR) (n=3; 30%), Sjögren syndrome (SS) (n=1; 10%), antiphospholipid syndrome (APS) (n=1; 10%) and autoinflammatory syndrome (WDR1 mutation) (n=1; 10%). Patients with RA, SS, PmR, and APS were clinically mild. RA patients were seronegative, non-erosive and without extraarticular involvement. Treatment and response are summarized in Table 1. All patients diagnosed with PMR were treated with glucocorticoids (prednisone 5 mg/12 hours), SS with hydroxychloroquine (HCQ) (200 mg/day), APS was anticoagulated with acenocumarol and one autoinflammatory syndrome was finally treated with baritinib (4 mg/day) after failure to anakinra (100 mg/day).ConclusionExcept in autoinflammatory syndrome, most rheumatic IMID associated to JAK-2 (V16F) mutation are clinically mild, and treatment and response of patients seems similar or even better than those without this mutation.Table 1.Treatment of 10 patients with rheumatic IMIDs and JAK-2 (V16F) mutation.Abbreviation:ANA: anakinra, BARI: baricitinib, NSAIDs: Non-Steroidal Anti-inflammatory Drugs, PDN: prdnisone, RA: Rheumatoid arthritis, SS: Sjögren syndrome, PMR: polymyalgia rheumatica.Disclosure of InterestsCarmen Álvarez-Reguera: None declared, Lara Sanchez-Bilbao: None declared, Sara Fernández López: None declared, Ana Batlle-López: None declared, Alba Herrero-Morant: None declared, David Martínez-López: None declared, Miguel Á. González-Gay Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen, Lilly and MSD, Grant/research support from: Abbvie, Pfizer, Roche, Sanofi and MSD., Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen, Lilly and MSD., Grant/research support from: Abbvie, MSD and Roche.
16
Aaramaa, H. K., P. Isomäki, N. Mars, M. Helminen, A. Kerola, A. Palomäki, K. Eklund, J. Gracia Tabuenca, and J. Sinisalo. "POS0324 RISK OF CARDIOVASCULAR COMORBIDITIES IN RHEUMATIC DISEASES." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 413.2–413. http://dx.doi.org/10.1136/annrheumdis-2022-eular.4456.
Full textAbstract:
BackgroundCardiovascular diseases (CVD’s) are the most significant comorbidities in rheumatic diseases, causing also increased mortality. [1,2] However, there is only limited data on how the risk of CV comorbidities varies between different rheumatic diseases.ObjectivesThe aim of our study was to estimate the risk of certain CV comorbidities across rheumatic diseases.MethodsThe ongoing FinnGen project links nationwide healthcare register data with genome data. The study (data freeze 7) included 321 302 individuals, and from this group we identified patients with seropositive (N=4293) and seronegative (N=1733) rheumatoid arthritis (RA), ankylosing spondylitis (AS, N=1247), psoriatic arthritis (PsA, N=1235), systemic lupus erythematosus (SLE, N=386), primary Sjogren’s syndrome (pSS, N=557) and gout (N=2178). Each patient was matched based on age, sex and municipality of residence with twenty individuals without any rheumatic conditions. The CV comorbidities studied were any CV disease (CVD), major coronary heart disease event (myocardial infarction and/or revascularization; CHD), ischemic stroke, atrial fibrillation and flutter (AF), deep vein thrombosis of lower extremities (DVT) and pulmonary embolism (PE), chronic heart failure (CHF) and valvular heart disease excluding rheumatic fever (VHD). From the prevalence of each CV disease among rheumatic disease cohorts, we calculated the risk ratio (RR) for each CV disease by comparing the prevalence of these diseases between rheumatic diseases and controls.ResultsThe average age at the time of diagnosis ranged from 39.6 to 64.4 years, and the average duration of follow-up varied from 9 to 19.5 years in different rheumatic diseases. The risk for any CVD was elevated in all rheumatic disease cohorts with RR varying from 1.14 in seropositive RA to 1.65 in SLE. SLE patients carried the highest relative risk for CV comorbidities, demonstrating over 2.5-fold risk for DVT/PE (RR 3.57), stroke (RR 2.57), CHF (RR 2.64) and VHD (RR 2.98). At least two-fold risk compared to controls was identified for AF (RR 2.03), DVT/PE (RR 2.44) and CHF (RR 3.03) in patients with gout, for DVT/PE (RR 2.15) and CHF (RR 2.0) in patients with pSS, and for DVT/PE (RR 2.03) in patients with PsA. Seropositive and seronegative RA demonstrated similar CV risk profiles. In patients with seropositive or seronegative RA, PsA, pSS or SLE, DVT/PE demonstrated the highest RR’s among various CV comorbidities.ConclusionThe risk of CV comorbidities is increased in all studied rheumatic diseases, with the largest effects observed in patients with SLE and gout. Among CV comorbidities, DVT/PE displayed the largest effect sizes in several rheumatic diseases. The current results further strengthen the importance of evaluating and treating risk factors for CV comorbidities across rheumatic diseases, focusing also to the excess risk for thromboses.References[1]Han C., Robinson DW Jr et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. J Rheumatol. 2006;33(11):2167-2172.[2]Avina-Zubieta JA, Choi HK et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008; 15;59(12):1690-1697.AcknowledgementsSpecial thanks to Finnish Foundation of Rheumatology Research and the Foundation of Maire Lisko for issuing research grants to help with the research process and writing of this abstract.Disclosure of InterestsHanna-Kaisa Aaramaa: None declared, Pia Isomäki Speakers bureau: Speaker or chair for AbbVie, Eli Lilly and Pfizer., Consultant of: Consultant for AbbVie, Eli Lilly, Pfizer, Roche and ViforPharma., Grant/research support from: A research grant from Pfizer., Nina Mars: None declared, Mika Helminen: None declared, Anne Kerola: None declared, Antti Palomäki Speakers bureau: Lecture free from Pfizer and Sanofi, Consultant of: Consulting fee from Abbvie, Amgen and Pfizer, Kari Eklund: None declared, Javier Gracia Tabuenca: None declared, Juha Sinisalo: None declared
17
Adami, Fassio, Rossini, Caimmi, Giollo, Orsolini, Viapiana, and Gatti. "Osteoporosis in Rheumatic Diseases." International Journal of Molecular Sciences 20, no. 23 (November 22, 2019): 5867. http://dx.doi.org/10.3390/ijms20235867.
Full textAbstract:
Osteoporosis is a chronic disease characterized by an increased risk of fragility fracture. Patients affected by rheumatic diseases are at greater risk of developing osteoporosis. The purpose of the present review is to discuss the pathogenesis, epidemiology, and treatment of osteoporosis in patients affected by rheumatic diseases with special focus for rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, systemic lupus erythematosus, systemic sclerosis, vasculitides, Sjogren syndrome, and crystal-induced arthritis.
18
Moreno-Arquieta, I. A., G. G. Sánchez Mendieta, D. E. Flores Alvarado, J. A. Esquivel Valerio, and D. Á. Galarza-Delgado. "AB0868-HPR ADHERENCE TO DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATIC DISEASES DURING COVID-19 PANDEMIC." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 1458.1–1458. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2131.
Full textAbstract:
Background:The pandemic COVID-19 has set a new challenge in adherence to treatment in patients with rheumatic diseases. Prior studies in Latin America had reported adherence of 16.4% on Rheumatoid Arthritis (RA) and 45.9% in Systemic Lupus Erythematous (SLE). There is evidence that these patients believe their treatment increases the risk and gravity of COVID-19 and therefore, suspending the treatment could reduce this risk. It has been shown that a “Good adherence” is associated to a better survival.Objectives:Describe the adherence to DMARDs in patients with Rheumatic diseases during COVID-19.Methods:Descriptive, cross-sectional, self-report study conducted in rheumatology outpatient clinic of University Hospital in Monterrey, México. Consecutive patients with RA, SLE, Inflammatory Myopathies and Systemic Sclerosis, were approached during their routine appointments, March 2020 to December 2020 period during COVID-19 pandemic. They were asked how many days of the month they took the DMARD indicated in the previous appointment, with Based on this, adherence was classified into four categories: Good 100-75% (> 21 days), Regular 74-50% (21-15 days), Bad 49-25% (14-8 days) and Null <25% (<7 days). Data was obtained from our internal electronic patient record registry and analyzed with SPSS V.22.Results:n (DMARDs)GoodRegularBadNulln (%)n (%)n (%)n (%)Rheumatoid Arthritis302255 (84.4)13 (4.3)20 (6.6)14 (4.6)Systemic Lupus Erithematous126111 (88)3 (2.3)8 (6.3)4 (3.1)Inflammatory Myopathies1110 (90.9)0 (0)1 (9)0 (0)Systemic Sclerosis3027 (90)2 (6.6)1 (3.3)0 (0)TOTAL469Conclusion:Despite what it is believed, patients are not changing therapeutic regimes. The adherence found in this group of patients was good, for the definition used in this study. It should be considered that the self-report method may overestimate adherence, so the data found must be correlated with objective methods in the future.References:[1]Resende Prudente L, Souza Diniz J, Matteucci Ferreira TXA, Marçal Lima D, Antônio Silva N, Saraiva G, et al. Medication adherence in patients in treatment for rheumatoid arthritis and systemic lupus erythematosus in a university hospital in Brazil. Patient Preference and Adherence. 2016:10 863–870.[2]Michaud K, Wipfler K, Shaw Y, et al. Experiences of patients with rheumatic diseases in the United States during early days of the COVID-19 pandemic. ACR Open Rheumatol 2020. doi:10.1002/acr2.11148.[3]Waimann ChA, Marengo MF, de Achaval S, Cox VL, Garcia-Gonzalez A, Reveille JD. Electronic Monitoring of Oral Therapies in Ethnically Diverse and Economically Disadvantaged Patients With Rheumatoid Arthritis. Arthritis & Rheumatism. 2013:6 1421-1429.Disclosure of Interests:None declared
19
Berard, E., T. Barnetche, L. Rouxel, C. Dutriaux, L. Dousset, S. Prey, M. Beylot-Barry, et al. "SAT0540 ONE-YEAR OUTCOMES AFTER RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS FROM CHECKPOINT INHIBITORS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1227.2–1227. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4366.
Full textAbstract:
Background:Description and initial management of rheumatic immune-related adverse-events (irAEs) from cancer immunotherapies have been reported by several groups but to date, few studies have evaluated the long-term outcomes and management of rheumatic irAEs (1).Objectives:To describe the long-term management and assess the one-year outcomes of patients who experienced rheumatic immune-related adverse events (irAEs) due to immune checkpoint inhibitors (ICI).Methods:This was a single-centre prospective observational study including patients referred for musculoskeletal symptoms while treated with ICI. After baseline rheumatological evaluation defining the clinical entity presented, follow-up visits were organised according to the type and severity of irAE. At one year, persistence of irAE, ongoing treatment, as well as cancer outcomes were assessed.Results:63 patients were included between September 2015 and June 2018. 24 patients (38%) presented with non-inflammatory musculoskeletal conditions managed with short-term symptomatic treatment and did not require specific follow-up. 39 patients (62%) experienced inflammatory manifestations, mimicking either rheumatoid arthritis (RA, n=19), polymyalgia rheumatica (PMR, n=16), psoriatic arthritis (PsA, n=3) and one flare of a preexisting axial spondyloarthritis. Overall, 32 patients (82%) received systemic glucocorticoids, with a median rheumatic dosage of 15mg/day (range: 5-60mg/day). None of the patients had to permanently discontinue ICI therapy for rheumatic irAE. 20 patients (67%) were still receiving glucocorticoids at one year, with a median dosage of 5mg/day (range: 2-20mg/day). Glucocorticoids were more frequently discontinued for patients with RA-like condition (44%) than PMR-like condition (23%), but no other predictive factor of glucocorticoids withdrawal could be identified. At one year, overall survival and progression-free survival were comparable between patients who were still receiving glucocorticoids for rheumatic irAE and patients who have discontinued. Eight patients required csDMARDs.Conclusion:At one year, a majority of patients required long-term low-dose glucocorticoids for chronic rheumatic irAE, which seems not altering oncological control.References:[1]Braaten TJ, Brahmer JR, Forde PM, et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. 2019 Sep 20.Disclosure of Interests:None declared
20
SPIES, CORNELIA M., MAURIZIO CUTOLO, RAINER H. STRAUB, GERD-RÜDIGER BURMESTER, and FRANK BUTTGEREIT. "More Night Than Day — Circadian Rhythms in Polymyalgia Rheumatica and Ankylosing Spondylitis." Journal of Rheumatology 37, no. 5 (April 1, 2010): 894–99. http://dx.doi.org/10.3899/jrheum.091283.
Full textAbstract:
The circadian rhythm of symptoms in patients with chronic inflammatory diseases is well known. Circadian rhythms could be used to identify targets for time-adapted antiinflammatory therapies, which are administered prior to the flare of cytokine synthesis and inflammatory activity. In recent years, the diurnal variations in rheumatoid arthritis have been described precisely for pain, stiffness, and functional disability, as well as the underlying cyclic variations in hormone levels and cytokine concentrations. This review summarizes the current knowledge on circadian rhythms in other rheumatic diseases, focusing on polymyalgia rheumatica and ankylosing spondylitis.
21
M.K.Osminina, M. K. Osminina, I. A. Dronov I.A.Dronov, S. S. Telkova S.S.Telkova, A. V. Skvortsov A.V.Skvortsov, and N. S. Podchernyaeva N.S.Podchernyaeva. "Vaccination of children with autoimmune rheumatic diseases. Current state of the problem." Voprosy praktičeskoj pediatrii 16, no. 3 (2021): 72–83. http://dx.doi.org/10.20953/1817-7646-2021-3-72-83.
Full textAbstract:
Vaccination of children with autoimmune rheumatic diseases is a significant problem since infectious diseases remain the main cause of complications of anti-rheumatic therapy and one of the leading causes of death in this category of patients. This review presents current information on the frequency of comorbid infections, the accumulated experience of vaccination in children with autoimmune rheumatic diseases. The recommendations of The European League Against Rheumatism (EULAR) for vaccination in paediatric patients with rheumatic diseases are presented in detail. The presence of rheumatic disease is not an exception for vaccination, it is recommended for all children following national guidelines. Non-live vaccines are effective and safe in paediatric patients with rheumatic diseases. Live vaccines are not recommended for patients receiving high doses of glucocorticoids, immunosuppressive and biologics therapy due to the risk of infectious complications. Vaccination against pneumococcal infection and seasonal influenzais are hihgly recommended. Key words: vaccination, children, autoimmune rheumatic diseases, guidelines, review
22
Álvarez-Reguera, C., L. Sanchez-Bilbao, A. Batlle-López, S. Fernández López, M. Á. González-Gay, and R. Blanco. "AB0825 JAK2 (V617F) MUTATION AND ASSOCIATION TO IMMUNE MEDIATED DISEASES. STUDY OF 130 PATIENTS FROM A SINGLE UNIVERSITY HOSPITAL." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 1436.2–1437. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2161.
Full textAbstract:
Background:Janus Kinases (JAK) are tirosin-kinases that can promote cytokine production in immune and hematopoietic cells. The JAK-2 (V617F) mutation is the most frequently detected mutation in myeloproliferative neoplasms (MPN) which include essential thrombocythemia (ET), polycythemia vera (PV), primary myelofibrosis (PMF) and undifferenciated MPN. JAK-2 (V617F) mutation displays a pro-inflammatory phenotype that may be associated to a higher risk of immune mediated diseases (IMID), thromboembolic complications or other cancers (1-3).Objectives:To evaluate the presence of a) IMID (rheumatic and non-rheumatic), b) cancer and, c) Deep vein thrombosis/ Venous thromboembolism (DVT/VTE) events in a cohort of patients with a positive JAK-2 (V617F) mutation.Methods:We studied all the patients diagnosed with a positive JAK-2 (V16F) mutation in a single University Hospital between January, 2004 and December, 2019.Results:The study included 130 patients (73 men/57 women; mean age, 70.1±14.5 years). They were diagnosed of ET (n=64, 49.2%), PV 46 (35.4%), undifferentiated MPN (n=12, 9.2%) and PMF (n=8, 6.1%). Of these patients, 54 (41.5 %) (44 non rheumatic and 10 rheumatic) were diagnosed with at least one IMID, 46 (35.4%) with other cancer different of MPN and 36 (27.7%) with DVT/VTE events. (Table 1/Figure 1).Conclusion:Due to its prevalence and potential complications, IMID should be taken into consideration when a patient is diagnosed with a positive JAK-2 (V617F) mutation.References:[1]Perner F, et al. Cells. 2019;8:854.[2]Xu Q, et al. Clin Rheumatol. 2020 Jul 16.[3]Hasselbalch HC, et al. 2020; 23;17(1):248.Table 1.Associated diseases in 130 patients with JAK2 (V617F) mutation. Data are n (%)Myeloproliferative neoplasms (MPN)130 (100) Essential thrombocythemia (ET)64 (49.2) Polycythemia vera (PV)46 (35.4) Undifferentiated MPN12 (9.2) Primary myelofibrosis (PMF)8 (6.5)Non-rheumatic IMID44 (33.8) Diabetes mellitus22 (50) Asthma10 (22.7) Psoriasis6 (13.6) Crohn disease2 (4.5) Autoimmune thyroiditis2 (4.5)Rheumatic IMID10 (7.7) Rheumatoid arthritis4 (40) Polymyalgia rheumatica3 (30) Sjögren disease1 (10) Antiphospholipid syndrome1 (10) Adult-onset Still’s disease1 (10)Malignancies different of MPN44 (33.8) Solid tumours // Hematologic malignancies // Skin cancer22 (50) // 13 (29.5) // 9 (20.4)Deep vein thrombosis/Venous thromboembolism (DVT/VTE) events35 (26.9)Figure 1.Associated diseases accordingly to the subtype of Myeloproliferative neoplasm. Data are n.ABBREVIATIONS: DVT/VTE: Deep vein thrombosis/ Venous thromboembolism. ET: Essential Thrombocythemia, IMID: Immune Mediated Diseases, PV: Polycythemia Vera; MPN: Myeloproliferative Neoplasms; PMF: Primary myelofibrosis; UMPN: Undifferenciated myeloproliferative neoplasms.Disclosure of Interests:Carmen Álvarez-Reguera: None declared, Lara Sanchez-Bilbao: None declared, Ana Batlle-López: None declared, Sara Fernández López: None declared, Miguel Á. González-Gay Speakers bureau: Abbvie, Pfizer, Roche, Sanofi and MSD., Grant/research support from: Abbvie, MSD, Janssen and Roche, Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen, Lilly and MSD., Grant/research support from: Abbvie, MSD and Roche
23
Au, Chi Kit, Tin Lok Lai, and Cheuk Wan Yim. "Role of Microbiome in Rheumatic Diseases." Hong Kong Bulletin on Rheumatic Diseases 17, no. 2 (December 29, 2017): 58–63. http://dx.doi.org/10.1515/hkbrd-2017-0010.
Full textAbstract:
AbstractMajority of rheumatic diseases are complex and multifactorial in etiology. Emerging studies has suggested that the change of human microbiota, especially in the gut, play a pivotal role in its pathogenesis. Dysequilibrium of the gut microbiota triggers the imbalance between pro- and anti- inflammatory immune responses and results in different rheumatic manifestations, such as rheumatoid arthritis (RA) and spondyloarthritis (SpA). In this article, current and future role of the human gut microbiota in rheumatic diseases are discussed.
24
Scotece, Morena, Javier Conde, Rodolfo Gómez, Verónica López, Jesús Pino, Antonio González, Francisca Lago, Juan J. Gómez-Reino, and Oreste Gualillo. "Role of Adipokines in Atherosclerosis: Interferences with Cardiovascular Complications in Rheumatic Diseases." Mediators of Inflammation 2012 (2012): 1–14. http://dx.doi.org/10.1155/2012/125458.
Full textAbstract:
Patients with rheumatic diseases have an increased risk of mortality by cardiovascular events. In fact, several rheumatic diseases such as rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, and ankylosing spondylitis are associated with a higher prevalence of cardiovascular diseases (CVDs). Although traditional cardiovascular risk factors have been involved in the pathogenesis of cardiovascular diseases in rheumatic patients, these alterations do not completely explain the enhanced cardiovascular risk in this population. Obesity and its pathologic alteration of fat mass and dysfunction, due to an altered pattern of secretion of proinflammatory adipokines, could be one of the links between cardiovascular and rheumatic diseases. Indeed, the incidence of CVDs is augmented in obese individuals with rheumatic disorders. Thus, in this paper we explore in detail the relationships among adipokines, rheumatic diseases, and cardiovascular complications by giving to the reader a holistic vision and several suggestions for future perspectives and potential clinical implications.
25
Evstigneeva, L. P. "Osteoporosis in rheumatic diseases." Medical alphabet, no. 33 (December 13, 2021): 64–75. http://dx.doi.org/10.33667/2078-5631-2021-33-64-75.
Full textAbstract:
The article presents a review of studies that have examined osteoporosis in rheumatic diseases, including rheumatoid arthritis, spondylarthritis, psoriatic arthritis, systemic connective tissue diseases, and systemic vasculitis. The review discusses the pathogenesis, diagnosis and treatment of osteoporosis in these diseases, presents the results of epidemiological studies assessing the risk factors and the prevalence of osteoporosis in rheumatic diseases. There was a high prevalence of osteoporosis and fractures in rheumatic diseases, exceeding the population, associated primarily with systemic and local inflammation, as well as with the intake of glucocorticoids. It is indicated that the existing strategies for the treatment of rheumatic diseases may partially reduce bone loss, but long-term administration of glucocorticoids, on the contrary, increase bone resorption. The review presents data on the medications for the treatment of osteoporosis and approaches to the treatment of glucocorticoid osteoporosis.
26
Schmidt, Zsuzsanna M., and Gyula Poor. "Polymyalgia Rheumatica, an Age-Related Rheumatic Disease." OBM Geriatrics 6, no. 3 (May 7, 2022): 1. http://dx.doi.org/10.21926/obm.geriatr.2203202.
Full textAbstract:
Polymyalgia rheumatica (PMR) is an age-related chronic inflammatory disease with rheumatic features at the fore. In addition to the high-grade systemic inflammation, it is characterized by typical “polymyalgic” musculoskeletal symptoms, including diffuse and severe pain and prolonged morning stiffness of the shoulder girdle, pelvic girdle, and neck. PMR is a member of the so-called giant cell arteritis complex; however, in spite of the marked systemic inflammation in PMR, the local vasculitis process aborts. The pathological background is synovitis, with a predominant inflammation of the extra-articular synovial structures. Synovitis of PMR is mild, transient, and non-erosive. Distal musculoskeletal symptoms are also observed but are more variable and less recognizable than the predominant proximal polymyalgic syndrome. PMR often overlaps with elderly-onset seronegative arthritides, elderly-onset rheumatoid arthritis, late-onset seronegative spondylarthritis, and the RS3PE1 syndrome. Although glucocorticoids are the cornerstone of PMR therapy, considerable hope is attached to tocilizumab, an IL-6 receptor inhibitor.
27
C, Hasina. "Rheumatic Fever Arthritis." Journal of Orthopaedics & Bone Disorders 3, no. 1 (2019): 1–2. http://dx.doi.org/10.23880/jobd-16000169.
Full text
28
Ahn, S. M., S. Hong, C. K. Lee, B. Yoo, J. S. Oh, and Y. G. Kim. "AB1443 INCIDENCE OF RHEUMATIC DISEASES DURING THE COVID-19 PANDEMIC IN KOREA: A NATIONWIDE CLAIMS STUDY." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 1827–28. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2835.
Full textAbstract:
BackgroundIn Korea, it has been reported that the incidence of some respiratory diseases and Kawasaki diseases has decreased compared to the previous year along with active non-pharmaceutical interventions in the early stages of the COVID-19 pandemic. Autoimmune inflammatory rheumatic disease (AIIRD) is mainly affected musculoskeletal organs and connective tissues due to impaired immune regulation. Although gout and osteoarthritis are rheumatic diseases, they are not a disease of the immune system, and are not included in the AIIRD.ObjectivesIn this study, we investigated the change and difference in the incidence rate of various rheumatic diseases during the COVID-19 pandemic after 2020.MethodsThe number of patients for each disease from January 2016 to December 2020 was obtained from the Korea Health Insurance Review and Assessment Service database. We compared the incidence of 9 rheumatic diseases [systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), ankylosing spondylitis (AS), Sjogren syndrome (SJS), Behcet’s disease (BD), inflammatory myositis (IIM), scleroderma, polymyalgia rheumatica (PMR), and gout] and hypertension before and after the COVID-19 outbreak. The incidence rates of patients before and after the COVID-19 outbreak were compared using the Poisson test.ResultsFrom 2016 to 2019, the prevalence of rheumatic diseases showed gradually increased. In 2020, the incidence of SLE, AS, SJS, BD, and IIM were significantly decreased compared to the previous 4 years. In contrast, the incidences of gout and hypertension during the COVID-19 pandemic period were significantly increased from the predicted values.ConclusionIn conclusion, we found that the incidence of many AIIRDs, including SLE, AS, SJS, BD, and IIM decreased despite the increased incidence of hypertension and gout during the COVID-19 pandemic.References[1]Huh K, Kim YE, Ji W et al. Decrease in hospital admissions for respiratory diseases during the COVID-19 pandemic: a nationwide claims study. Thorax 2021;76:939-41.[2]Kang JM, Kim YE, Huh K et al. Reduction in Kawasaki Disease After Nonpharmaceutical Interventions in the COVID-19 Era: A Nationwide Observational Study in Korea. Circulation 2021;143:2508-10.Table 1.Cumulative incidence of rheumatic diseases and HTN (by Poisson test)Mean (2016-2019)Observed (2020.1~12)Rate ratio (95%CI)P valueSLE5371.34541.00.844 (0.811, 0.878)<0.001BD3598.33057.00.848 (0.808, 0.890)<0.001AS11679.510934.00.935 (0.910, 0.959)<0.001SJS7913.57280.00.918 (0.890, 0.948)<0.001IIM839.8397.00.472 (0.418, 0.532)<0.001RA17490.317342.00.990 (0.969, 1.011)0.343SSc592.8557.00.938 (0.834, 1.054)0.288PMR1072.01152.01.073 (0.986, 1.167)0.098Gout129543.0131133.01.011 (1.003, 1.018)0.007HTN680943.2696391.01.021 (1.018, 1.024)<0.001SLE; systemic lupus erythematosus, BD; Behçet disease, AS; ankylosing spondylitis, SSc; systemic sclerosis, IIM; idiopathic inflammatory myositis, RA; rheumatoid arthritis, SJS; Sjogren syndrome, PMR; polymyalgia rheuamtica, HTN; hypertension, CI; confidence interval.Disclosure of InterestsNone declared
29
Mc-Cutchan, R., S. Maier, V. Winkler, B. Gruber, and M. Schirmer. "AB1303-HPR TIME UNTIL DIAGNOSIS IN RHEUMATOLOGICAL PRACTICE: RESULTS FROM A CROSS-SECTIONAL MIDDLE-EUROPEAN COHORT COMPARED TO DATA FROM A SYSTEMATIC LITERATURE REVIEW." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1942.1–1942. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3724.
Full textAbstract:
Background:The time from first symptom to diagnosis (= diagnostic delay) is considered as key factor for better outcome in many chronic inflammatory rheumatic diseases, especially for rheumatoid arthritis (RA) and vasculitides like giant cell arteritis (GCA). A longer diagnostic delay may cause pain, reduced functionality, reduced life-quality and increased morbidity, as well as structural damages of the organs linked with higher mortality. This retrospective study assessed the diagnostic delay in consecutive Middle-European outpatients and compared results with those of a systematic literature review (SLR).Objectives:To compare disease-specific diagnostic delays of consecutive rheumatic patients with international data from a systematic literature review.Methods:Charts of a single-centre cohort with consecutively recruited patients were retrospectively reviewed for patients’ and diseases’ characteristics at a Middle-European university outpatient clinic for rheumatology. A SLR was performed according to PRISMA guidelines.Results:The average mean ± SD time from first symptom to established diagnosis was 7.9 ± 11.7 (0.02-56.7) years. Spondyloarthritis patients showed the longest diagnostic delay with 13.1 ± 14.2 (0.1-56.7) years, whereas polymyalgia rheumatica-patients had the shortest diagnostic delay with 1.5 ± 0.4 (0.3-18.0) months. In the SLR, most data for diagnostic delays are comparable to the Innsbruck cohort, but the diagnostic delay for psoriatic arthritis in Innsbruck is longer than in the Danish DANBIO registry (p<0.001). Independent risk factors for prolonged diagnostic delays could not be identified.Conclusion:For this Middle-European area, initiatives are justified especially to shorten diagnostic delays of SpA and PsA.References:[1]O’Dell JR. Treating rheumatoid arthritis early: A window of opportunity? Arthritis Rheum. 2002;46:283–5.[2]Seo MR, Baek HL, Yoon HH, Ryu HJ, Choi HJ, Baek HJ, et al. Delayed diagnosis is linked to worse outcomes and unfavourable treatment responses in patients with axial spondyloarthritis. Clin Rheumatol. 2015;34:1397–405.[3]Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74:1045–50.[4]Dejaco C, Brouwer E, Mason JC, Buttgereit F, Matteson EL, Dasgupta B. Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nat Rev Rheumatol. Nature Publishing Group; 2017;13:578–92.Acknowledgments:We acknowledge and thank all patients who could be recruited to the SolutionX project. Ethical vote was obtained by the local ethics committee of the Medical University of Innsbruck (AN2017-0041 370/4.18).Disclosure of Interests:Rick Mc-Cutchan: None declared, Sarah Maier: None declared, Valentin Winkler: None declared, Bernhard Gruber: None declared, Michael Schirmer Grant/research support from: total <3000.- €, Speakers bureau: total <3000.- €
30
Camellino, D., and C. Dejaco. "Update on treatment of polymyalgia rheumatica." Reumatismo 70, no. 1 (March 27, 2018): 59. http://dx.doi.org/10.4081/reumatismo.2018.1062.
Full textAbstract:
Polymyalgia rheumatica (PMR) is the second most common inflammatory rheumatic disease in the elderly after rheumatoid arthritis. It is clinically characterised by pain and stiffness in the neck, proximal shoulder and hip girdle. Glucocorticoids (GCs) are the cornerstone of PMR treatment, but they are associated with potentially severe side effects. Among GC-sparing agents, methotrexate revealed a modest benefit in clinical trials, and recently, there have been promising reports from tocilizumab. In this review, we summarize the available evidence on the treatment of PMR and the possible role in the future of other agents under investigation.
31
Xiao, Yan, Lin Zeng, Qinglin Shen, Zhiyong Zhou, Zhifang Mao, Qin Wang, Xiquan Zhang, Yingliang Li, and Weirong Yao. "Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors." Journal of Immunology Research 2020 (August 4, 2020): 1–8. http://dx.doi.org/10.1155/2020/2640273.
Full textAbstract:
Immune checkpoint inhibitors (ICIs) have completely changed the treatment of cancer, and they also can cause multiple organ immune-related adverse reactions (irAEs). Among them, rheumatic irAE is less common, mainly including inflammatory arthritis, rheumatic myalgia/giant cell arteritis, inflammatory myopathy, and Sjogren’s syndrome. For oncologists, rheumatism is a relatively new field, and early diagnosis and treatment is very important, and we need to work closely with experienced rheumatologists. In this review, we focused on the incidence, clinical characteristics, and treatment strategies of rheumatic irAE.
32
Mazurov, Vadim I., Irina B. Belyaeva, Lubov E. Sarantseva, Anton L. Chudinov, Roman A. Bashkinov, Evgeni A. Trofimov, Olga A. Smulskaya, Oksana V. Inamova, Marianna S. Petrova, and Evgeni S. Melnikov. "Impact of a new coronavirus infection on the clinical course of immunoinflammatory rheumatic diseases." HERALD of North-Western State Medical University named after I.I. Mechnikov 13, no. 2 (August 30, 2021): 39–47. http://dx.doi.org/10.17816/mechnikov72269.
Full textAbstract:
BACKGROUND: The COVID-19 pandemic poses a particular threat to patients suffering from immunoinflammatory rheumatic diseases. New coronavirus infection has been found to be accompanied by the development of a wide range of extrapulmonary clinical and laboratory manifestations, which are characteristic of a number of immunoinflammatory rheumatic diseases.
AIM: To evaluate the features of the clinical course of immunoinflammatory rheumatic diseases in patients who underwent new coronavirus infection.
MATERIALS AND METHODS: The clinical course of immunoinflammatory rheumatic diseases was analyzed in 324 patients who underwent new coronavirus infection from March 2020 to February 2021 and were treated at the Clinical Rheumatology Hospital No. 25, Saint Petersburg, for exacerbation of the underlying disease.
RESULTS: Analysis showed that the risk factors for severe new coronavirus infection in patients with immunoinflammatory rheumatic diseases were: age over 60, comorbidities, use of prednisolone in a dose greater than 12,5 mg, and ESR values 40 mm/hour before the development of new coronavirus infection. There was no effect of immunosuppressive and biological therapy on the severity of the course of viral infection. There was no effect of immunosuppressive therapy and biological therapy on the severity of the course of viral infection in patients with immunoinflammatory rheumatic diseases. The development of the postinfectious syndrome was observed in 1/4 of patients, which was characterized by the formation of postinfectious arthritis in 3,6% of patients, transformation of undifferentiated arthritis into various rheumatic diseases in 49% of patients (more often into early rheumatoid arthritis), as well as exacerbation of the underlying disease in 83,4% of patients with an advanced stage of rheumatoid arthritis. In patients with mixed connective tissue disease, there was a significant increase in immunologic activity due to antinuclear factor (up to a maximum of 1:163 840). Clinical cases of the development of arthritis associated with viral infection and the debut of rheumatoid arthritis after an new coronavirus infection are presented.
CONCLUSIONS: New coronavirus infection in the cohort of patients with immunoinflammatory rheumatic diseases observed in the Clinical Rheumatology Hospital No. 25, Saint Petersburg, proceeded in the variant of medium severity in half of patients, initiated the development of lung lesions in 68,6% of patients, arthritis associated with viral infection in 3,6% of patients, immunoinflammatory rheumatic diseases which transformed from undifferentiated arthritis in 49% of cases and exacerbation of the main disease in an overwhelming number of patients. Patients with immunoinflammatory rheumatic diseases have a high risk of adverse outcome of new coronavirus infection, especially in cases of unstable course of the disease or exacerbation of this group of diseases.
33
Benesova, K., L. Diekmann, H. M. Lorenz, K. Jordan, and J. Leipe. "OP0270 TRHEUMA REGISTRY EXPLORES CHARACTERISTICS AND SUITABLE DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS (IRAES)." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 168.1–169. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3790.
Full textAbstract:
Background:Reports of rheumatic immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICPi) have recently attracted new attention to the complex interrelations of malignancies andrheumatic and musculoskeletal diseases (RMDs). Since those two entities represent two sides of a dysregulated immune response, further research on rheumatic irAEs and mechanisms underlying the better tumor response rates in irAE-affected patients may contribute to a better understanding of the different pathophysiology characterizing tumor and rheumatic disease.Objectives:Given the heterogeneity of the patient population with rheumatic irAEs, a registry-based study has been conducted to provide first evidence regarding characteristics of rheumatic irAEs and further insights into the optimal diagnostic and therapeutic management of rheumatic irAEs.Methods:The TRheuMa registry is a long-term, open-end observational study of a patient cohort suffering from rheumatic symptoms as a result of ICPi or other cancer therapies. The TRheuMa registry is one of the three subregistries of the MalheuR project, a registry-based study initiated in July 2018 at the at the university hospital Heidelberg to explore interrelations of malignancies and RMDs.Results:Over 18 months, 52 of 63 patients in the TRheuMa registry were recruited with a rheumatic irAE under ICPi treatment (pembrolizumab n=21, nivolumab n=28, ipilimumab n=11, durvalumab n=1, atezolizumab n=2, avelumab n=1, history of >1 ICPi n=11). Of the 52 patients, 22 (42.3%) had non-small cell lung cancer and 23 (44.2%) had a melanoma. Eight (15.3%) patients experienced a flare of a preexisting RMD under ICPi treatment. The remaining 44 patients withde novoirAEs were characterized by rheumatoid arthritis-like (20.5%) or polymyalgia rheumatica-like (18.1%) and psoriatic or other spondyloarthritis-like phenotypes (50.0%). However, laboratory findings differed from classical RMDs with elevated CRP-levels in 73.1% particularly in psoriatic arthritis-like, but not necessarily in polymyalgia rheumatica-like irAEs. On the contrary, autoantibody positivity was very rare. The majority of patients (78.8%) showed signs of inflammation upon ultrasound examination.Based on the severity of signs and symptoms as well as treatment response, we developed a therapeutic algorithm for rheumatic irAEs: non-steroidal anti-inflammatory drugs and/or low dosed glucocorticoids (≤10mg prednisone equivalent) as first treatment step were sufficient for 75% patients, whereas 17.3% required higher dosed glucocorticoids and 11.5% patients required further treatment with a cs- or bDMARD. In two cases ICPi-treatment was discontinued on patients’ request due to the pain and functional impairment caused by the rheumatic irAE, although a satisfactory symptom control was reached in the further course.Complete remission of cancer was observed in 43.5% of melanoma patients, 66.7% experienced additional severe irAEs in other organ systems.Conclusion:Overall, data from the TRheuMa-registry show that rheumatic irAEs mostly resemble classical RMDs, however show distinct characteristics. Our diagnostic and therapeutic management of rheumatic irAEs demonstrated efficacy in the majority of patients. These findings contribute to the further understanding of rheumatic irAEs and malignancies. Future research agenda includes a correlation of irAE severity with tumor response.Disclosure of Interests:Karolina Benesova Grant/research support from: Study grants for SCREENED study by Abbvie, Novartis and Rheumaliga Baden-Württemberg, Consultant of: One-time participation in Novartis advisory board., Leonore Diekmann: None declared, Hanns-Martin Lorenz Grant/research support from: Consultancy and/or speaker fees and/or travel reimbursements: Abbvie, MSD, BMS, Pfizer, Celgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag, Astra-Zeneca, Lilly. Scientific support and/or educational seminars and/or clinical studies: Abbvie, MSD, BMS, Pfizer, Celgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag, Astra-Zeneca, Lilly, Baxter, SOBI, Biogen, Actelion, Bayer Vital, Shire, Octapharm, Sanofi, Hexal, Mundipharm, Thermo Fisher., Consultant of: see above, Karin Jordan Consultant of: Consultancy and/or speaker fees: MSD, Merck, Amgen, Hexal, Riemser, Helsinn, Tesaro, Kreussler, Voluntis, Pfizer, Pomme-med., Jan Leipe Grant/research support from: Consultancy and speaker fees: Abbvie, AstraZeneca, BMS, Celgene, Hospira, Janssen-Cilag, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB. Scientific support: Novartis, Pfizer., Consultant of: Consultancy and speaker fees: Abbvie, AstraZeneca, BMS, Celgene, Hospira, Janssen-Cilag, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB. Scientific support: Novartis, Pfizer., Speakers bureau: Abbvie, AstraZeneca, BMS, Celgene, Hospira, Janssen-Cilag, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB
34
Hmamouchi, I., F. Paruk, S. A. A. Tabra, K. Maatallah, A. Bouziane, R. Abouqal, Y. El Miedany, A. EL Maghraoui, and A. A. Kalla. "AB1031 PREVALENCE OF GLUCOCORTICOID INDUCED OSTEOPOROSIS IN AFRICAN ADULT PATIENTS WITH CHRONIC RHEUMATIC DISEASES. A SYSTEMATIC REVIEW AND META-ANALYSIS." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 1639.1–1639. http://dx.doi.org/10.1136/annrheumdis-2022-eular.4288.
Full textAbstract:
BackgroundGlucocorticoid (GC) use is well established in the treatment of rheumatics diseases, particularly rheumatoid arthritis (RA). The use of low dose GC has been endorsed by EULAR recommendations for the management of rheumatic and musculoskeletal diseases even if in the context of SARS-CoV-2, but long-term use is generally discouraged.ObjectivesTo estimate the prevalence of glucocorticosteroids induced osteoporosis (GIOP) on bone mineral density (BMD) in African adult patients with inflammatory rheumatic diseases.MethodsFor this systematic review and meta-analysis, PubMed, Google Scholar, Scopus and African index medicus were systematically searched up to December 2020 without language restrictions. We included studies as follows: population-based or hospital-based study, study with sufficient information to estimate the prevalence of GIOP and osteoporotic fractures in African patients with rheumatic disease. Searches were limited to peer-reviewed full text articles. A standardized data extraction form was used to collect information from eligible studies. A random-effects meta-analysis was conducted to obtain the pooled prevalence of GIOP in these studies. The meta-analysis was stratified by geographical region. The study is registered with PROSPERO, number CRD42021256252.ResultsOur search identified 8571 studies, of which 8 studies were included in the systematic review from only four African countries and 7 studies in the meta-analysis. The pooled prevalence of osteoporotic fractures in our study was 47.7% (95% CI 32.9–62.8) with 52.2% (95% CI 36.5-67.6) in North Africa and 15.4% (95% 1.9-45.4%) in South Africa (SA). There was no evidence of publication bias, although heterogeneity was high (p=0.018). There was no data from sub-Saharan Africa apart from the two studies from SA.ConclusionThe overall prevalence of GIOP in African adult patients with inflammatory rheumatic diseases was high at 47.7% (95% CI 32.9–62.8). Meta-analysis calculation revealed patient geographic origin as possible confounding factors of the proportion outcomes and further studies are required.References[1]Landewé RB, Machado PM, Kroon F, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2Annals of the Rheumatic Diseases 2020;79:851-858.Disclosure of InterestsNone declared
35
Iordache, Cristina, Bogdan Vascu, Eugen Ancuta, Rodica Chirieac, Cristina Pomirleanu, and Codrina Ancuta. "Immuno-biological Assessments of Temporomandibular Joint Disease in Patients with Immune-mediated Rheumatic Conditions. A cross sectional study of 273 cases." Revista de Chimie 68, no. 12 (January 15, 2018): 2987–91. http://dx.doi.org/10.37358/rc.17.12.6023.
Full textAbstract:
Temporomandibular joint (TMJ) is commonly involved in various immune-mediated rheumatic disorders accounting for significant disability and impaired quality of life. The aim of our study was to assess inflammatory and immune parameters in patients with TMJ arthritis related to rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) and to identify potential relation with severity and dysfunction of TMJ pathology. We performed a cross-sectional study in a cohort of 433 consecutive RA, 32 JIA, 258 AS, and 103 PsA. Only patients presenting with clinically significant TMJ involvement (273) related to their rheumatic condition were included in the final analysis. TMJ involvement is traditionally described in chronic inflammatory rheumatic disorders, particularly in patients with higher levels of inflammation as detected in rheumatoid arthritis and psoriatic arthritis. Disease activity and severity, as well as biological and positive serological assessments (rheumatoid factor, anti-cyclic citrullinated peptide, IL-1) remain significant determinants of the severity of TMJ arthritis.
36
Elkayam, Ori. "Safety and Efficacy of Vaccination Against Influenza in Patients With Rheumatoid Arthritis." Clinical and Developmental Immunology 13, no. 2-4 (2006): 349–51. http://dx.doi.org/10.1080/17402520600589613.
Full textAbstract:
Vaccination against influenza is currently recommended for patients with rheumatoid arthritis (RA). The safety and efficacy of vaccination in patients suffering from rheumatic diseases is still a matter of debate. This review summarizes the studies performed on the safety and immunogenicity of influenza vaccination in patients with RA as well as the rheumatic complications of the vaccine in otherwise healthy persons. Several trials have shown that the vaccine induces an adequate humoral response and does not induce clinical exacerbation of RA. Rheumatic complications (mainly vasculitis) following influenza vaccination in the general population are scarce.
37
Mangusheva, M. M. "Treatment of rheumatoid arthritis patients with diucciphone." Kazan medical journal 67, no. 5 (September 15, 1986): 330–33. http://dx.doi.org/10.17816/kazmj70585.
Full textAbstract:
As for most systemic connective tissue diseases, in rheumatoid arthritis the questions of etiology have not yet been resolved; therefore, pathogenetic therapy is considered to be reasonable. Since inflammation is the most constant clinical and anatomical manifestation of rheumatic diseases, the anti-inflammatory effect can be generalized as the main goal of anti-rheumatic treatment.
38
Sari, Sinta Purnama, and Fitrianola Rezkiki. "Penatalaksanaan Pasien Rheumatoid Arthritis Berbasis Evidence Based Nursing : Studi Kasus." REAL in Nursing Journal 3, no. 1 (May 1, 2020): 49. http://dx.doi.org/10.32883/rnj.v3i1.778.
Full textAbstract:
<p><strong><em>Background:</em></strong><em> </em><em>One of the chronic diseases is rheumatoid arthritis (RA) is the most common auto immune disease, which is inflammation of the joints that occurs in adulthood and the elderly. According to the American Collage Of Rheumatology, 2015, rheumatoid arthritis has a significant negative impact on the ability to move, both work and household chores and affect quality of life and increase mortality</em><em>. </em><em>Indications of an increase in cases of rheumatism in the community one of them because of the lack of family attention to the prevention and care of family members who have rheumatic diseases. </em><strong><em>Aim</em></strong><em>: To find out Family Nursing Care with the Application of Complementary Therapy in Rheumatism Cases in </em><em>one of Kanagarian Sumatera Barat</em><em>.</em><em> </em><strong><em>Method</em></strong><em>: </em><em>In implementation, complementary therapy is applied to Rheumatic patients, namely through routine health checks, physical activity, rheumatic diet, gymnastics elderly, and consumption fro.</em><em> </em><strong><em>Results</em></strong><em>: </em><em>Rheumatism pain that was experienced Ny. Z has decreased from pain scale 6 (moderate) to 2 (mild) after ingestion of the frost for ± 6 days</em><em>.</em><em> </em><strong><em>Conclusion</em></strong><em>: </em><em>: </em><em>The application of complementary therapies showed improvement in patients suffering from rheumatism, therefore, the application of evidence-based nursing in providing nursing care is recommended</em><em>.</em><em> </em><em></em></p>
39
Rennebohm, Robert M. "Rheumatic Diseases of Childhood." Pediatrics In Review 10, no. 6 (December 1, 1988): 183–90. http://dx.doi.org/10.1542/pir.10.6.183.
Full textAbstract:
The pediatrician frequently encounters children and adolescents with musculoskeletal complaints that raise the possibility of rheumatic disease. The purposes of this article are: to review an approach to the evaluation of "joint" symptoms and to review the pharmacology, use, and adverse effects of nonsteroidal anti-inflammatory drugs. RHEUMATOLOGIC HISTORY Systematic collection of the historical details is fundamental in the evaluation of "joint" complaints (Table 1). Age and Sex The child's age and sex provide initial clues. For example, suspicion that a young girl (less than 5 years of age) with knee swelling might have monoarticular juvenile rheumatoid arthritis is heightened simply because of her age and sex. (At onset of their disease, almost 20% of all patients with juvenile rheumatoid arthritis are young girls with pauciarthritis, most commonly involving the knee.) Suspicion that an older boy (10 years of age or older) with axioskeletal complaints might have an enthesopathy syndrome is increased, in part, because of his age and sex. of the age and sex predilections of various rheumatic conditions is, therefore, helpful. Chief Complaint The chief complaint is often directive. For example, the complaint "his knees hurt every night" or "his legs hurt at night" is not characteristic of children who have juvenile rheumatoid arthritis or other well-defined inflammatory arthritides.
40
Mustika, I. Wayan, and Ni Putu Indah Mas Pratiwi. "Behavior to Overcome Rheumatic Pain in the Elderly." Journal of Drug Delivery and Therapeutics 12, no. 5 (September 15, 2022): 114–18. http://dx.doi.org/10.22270/jddt.v12i5.5651.
Full textAbstract:
Rheumatism is an autoimmune disease in which the joints experience inflammation, resulting in swelling, pain and often causes damage to the inside of the joints. The high incidence of rheumatism in the elderly is due to the demographic characteristics of the elderly and their behavior in dealing with rheumatic pain is not maximal. The purpose of this study is to describe the behavior of dealing with rheumatic pain in the elderly in Mengwitani Village, Mengwi District, Badung Regency in 2021. This research is a descriptive study using a cross sectional approach. The sampling method in this study is to use non-probability sampling with consecutive sampling. The research was conducted in January - April 2021 in Mengwitani Village with a total sample of 66 respondents. The results of this study, in terms of the characteristics of the respondents, found that the most age suffered from rheumatic pain was 60-74 years, 50 respondents (75.8%), with the most gender being 43 respondents (65.2%), the most education was SD 53 respondents (80, 3%), and most jobs are traders 24 respondents (36.4%). Based on the results of the research on the behavior of dealing with rheumatic pain in the elderly, a small proportion of them had less knowledge as much as 8 respondents (12.1%), most of them had sufficient attitudes, namely 53 respondents (80.3%), and 24 respondents (36.4%) have actions that are classified as good in dealing with rheumatic pain. For the elderly it is recommended to make lifestyle changes so that they can reduce the risk of rheumatism
41
Korolev, M. A., E. A. Letyagina, and N. E. Banshchikova. "Rheumatic polymyalgia on the background of prostate adenocarcinoma." Clinical Medicine (Russian Journal) 98, no. 2 (July 15, 2020): 153–56. http://dx.doi.org/10.30629/0023-2149-2020-98-2-153-156.
Full textAbstract:
Paraneoplastic syndromes diagnosed in 7–10% of patients with malignancies in general. PNS accompany bronchogenic lung, breast, ovarian, prostate, kidney and uterus cancers most often. Neoplastic process can cause by both the acute and the chronic inflammatory response with pathologic changes of the connective tissues and vascular in various organs and systems. Diagnosis of paraneoplastic syndromes is difficult often. However, some signs should cause of rheumatologist the oncologic alertness, which were found in patients with rheumatic masks of neoplasms. Among such signs include: the occurrence of rheumatic diseases in an abnormal age; the absence of sexual dimorphism, is typical of many rheumatic diseases; the difference between the severity of clinical manifestations and the general condition of the patient with an index of inflammatory activity; the absence of separate clinical and laboratory signs typical one or another rheumatic disease; the appearance of new symptoms, not characteristic of the rheumatic diseases. As a clinical example to illustrate the difficulty of diagnosis, this article describes a clinical case of adenocarcinoma of the prostate in 74-year-old men presenting as polymyalgia rheumatica.
42
Khabirov, R. A. "Muscular syndrome in patients with inflammatory and degenerative diseases of joints and vertebral column." Kazan medical journal 80, no. 2 (March 25, 1999): 113–16. http://dx.doi.org/10.17816/kazmj65368.
Full textAbstract:
The manifestations of muscular syndrome affecting the gravity and prediction of the disease take place in the most widespread and invalidizing rheumatic diseases: osteoarthrosis, rheumatoid arthritis and ankylosing spondylarthritis. Paraclinical studies showed heterogeneity of pathogenetic mechanisms in lesion of skeletal muscles in rheumatic diseases. The differentiated methods of the treatment of patients with osteoarthrosis, rheumatoid arthritis and ankylosing spondylarthritis taking into account the clinical picture and pathogenesis of muscular syndrome, as well as the diagnosis criteria and classification of muscular system lesion are suggested.
43
Svartz, Nanna. "IS “MUSCULAR RHEUMATISM” A RHEUMATIC DISEASE?" Acta Medica Scandinavica 142, S266 (April 24, 2009): 915–17. http://dx.doi.org/10.1111/j.0954-6820.1952.tb13440.x.
Full text
44
GADDY, JASMINE R., EVAN S. VISTA, JULIE M. ROBERTSON, AMY B. DEDEKE, VIRGINIA C. ROBERTS, WENDY S. KLEIN, JEREMY H. LEVIN, et al. "Rheumatic Disease Among Oklahoma Tribal Populations: A Cross-sectional Study." Journal of Rheumatology 39, no. 10 (August 15, 2012): 1934–41. http://dx.doi.org/10.3899/jrheum.110984.
Full textAbstract:
Objective.Rheumatic diseases cause significant morbidity within American Indian populations. Clinical disease presentations, as well as historically associated autoantibodies, are not always useful in making a rapid diagnosis or assessing prognosis. The purpose of our study was to identify autoantibody associations among Oklahoma tribal populations with rheumatic disease.Methods.Oklahoma tribal members (110 patients with rheumatic disease and 110 controls) were enrolled at tribal-based clinics. Patients with rheumatic disease (suspected or confirmed diagnosis) were assessed by a rheumatologist for clinical features, disease criteria, and activity measures. Blood samples were collected and tested for common rheumatic disease autoantibodies [antinuclear antibody (ANA), anti-cyclic citrullinated peptide antibodies (anti-CCP), rheumatoid factor (RF), anti-Ro, anti-La, anti-Sm, anti-nRNP, anti-ribosomal P, anti-dsDNA, and anticardiolipins].Results.In patients with suspected systemic rheumatic diseases, 72% satisfied American College of Rheumatology classification criteria: 40 (36%) had rheumatoid arthritis (RA), 16 (15%) systemic lupus erythematosus, 8 (7%) scleroderma, 8 (7%) osteoarthritis, 4 (4%) fibromyalgia, 2 (2%) seronegative spondyloarthropathy, 1 Sjögren’s syndrome, and 1 sarcoidosis. Compared to controls, RA patient sera were more likely to contain anti-CCP (55% vs 2%; p < 0.001) or RF IgM antibodies (57% vs 10%; p < 0.001); however, the difference was greater for anti-CCP. Anti-CCP positivity conferred higher disease activity scores (DAS28 5.6 vs 4.45; p = 0.021) while RF positivity did not (DAS28 5.36 vs 4.64; p = 0.15). Anticardiolipin antibodies (25% of rheumatic disease patients vs 10% of controls; p = 0.0022) and ANA (63% vs 21%; p < 0.0001) were more common in rheumatic disease patients.Conclusion.Anti-CCP may serve as a more specific RA biomarker in American Indian patients, while the clinical significance of increased frequency of anticardiolipin antibodies needs further evaluation.
45
Naseem, Sajid, Ambreen Zahoor, Zaidan Idrees Choudhary, and Tania Sultana. "A study on prescribing patterns in patients with rheumatoid arthritis." Professional Medical Journal 28, no. 7 (July 1, 2021): 1044–48. http://dx.doi.org/10.29309/tpmj/2021.28.07.6137.
Full textAbstract:
Objective: The aim of this study was to assess the prescribing patterns and frequency of use of various drug classes in patients with rheumatoid arthritis in a teaching hospital in Islamabad, Pakistan. Study Design: Descriptive Cross Sectional study. Setting: Medical Outpatient Department of HBS General Hospital, Islamabad. Period: August 2018 to March 2019. Material & Methods: Patients of rheumatoid arthritis were included in the study using non-probability consecutive sampling technique. Socio-demographic details and medication history was collected on pre-designed proforma. Data was analyzed using SPSS version 22. Results: A total of 112 patients were included in the study.108 patients (96.4%) were using disease modifying anti-rheumatic drugs. The most prescribed medication in the patients was methotrexate (n=82, 73%). One disease modifying anti-rheumatic drugs with a steroid was the preferred combination (n=32, 28%). Non-steroidal anti-inflammatory drugs (21%) and steroids (20%) were the other major drug classes among the total medications prescribed. Only one patient included in the study was using biologics. Conclusion: Conventional disease modifying anti-rheumatic drugs in combination with steroids and non-steroidal anti-inflammatory drugs are the preferred therapy in patients of Rheumatoid arthritis in local settings. Methotrexate is the most commonly used disease modifying anti-rheumatic drugs. The use of biological agents remains low as compared to the developed world owing to their high cost.
46
Nuraini, Nuraini, and Amrina Rosyada. "The Effect of Obesity and Other Factors towards On the Increased Risk of Rheumatism in Indonesia (Analysis of IFLS 2014)." Jurnal Ilmu Kesehatan Masyarakat 12, no. 1 (March 31, 2021): 77–87. http://dx.doi.org/10.26553/jikm.2021.12.1.77-87.
Full textAbstract:
The number of people with rheumatism worldwide has reached 355 million, and this is estimated by 2025, suggesting that more than 25% will experience paralysis. This study aims to determine obesity and other factors related to the increased risk of rheumatic diseases in Indonesia, the method used was data analysis using a complex sample survey. It used 2014 IFLS data and a cross sectional study design, as well as a multistage random sampling with a total of 29,106 respondents, and the results showed that the prevalence of rheumatic disease in Indonesia was 5.2% in 2014. The most dominant and unmodifiable variable that influenced incidence was gender (PR=1.686; 95% CI=1.488-1.910). Meanwhile, obesity is the most dominant and modifying variable that influences the incidence of rheumatic disease (PR=1.630; 95% CI=1.433-1.855). Factors that are simultaneously related to the increased risk of rheumatic diseases include age, gender, education, physical activity, protein consumption, obesity, and accident history. Considering the results, patients need to eat healthy and low purine foods, as well as implementing other healthy lifestyles such as appropriate, adequate, and regular physical activities in order to reduce the risk of rheumatism.
47
Espinosa Banuelos, L. G., M. E. Corral Trujillo, C. M. Skinner Taylor, L. Pérez Barbosa, R. A. Rodriguez Chavez, A. Y. Lujano Negrete, R. Moyeda Martinez, A. Cárdenas, and D. Á. Galarza-Delgado. "AB0658 FEAR OF COVID-19 IN POSTPARTUM WOMEN WITH RHEUMATIC DISEASE." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 1361–62. http://dx.doi.org/10.1136/annrheumdis-2021-eular.854.
Full textAbstract:
Background:In Mexico, the SARS-CoV-2 pandemic has totaled almost two million cases and exceeded 150,000 deaths (29/01/2021). Currently, COVID-19 has become the leading cause of death in pregnant women in Mexico. COVID-19 has additionally impacted the psychological health of individuals including women with rheumatic diseases.Objectives:The aim of this study is to compare the Fear of COVID-19 Scale (FCV-19S) in postpartum women with and without autoimmune rheumatic diseases.Methods:A cross-sectional, descriptive, and comparative study was conducted. The Spanish FCV-19S version was applied by telephone or e-mail. The instrument consists of seven items, each with a five-point Likert scale of options. The participant must choose the options that best represent their perception about the statements presented. The maximum possible total is 35 points. Sociodemographic information was collected from the clinical charts. The Kolmogorov-Smirnov test was used to determine normality of the data. Statistical analysis was done using the Mann-Whitney U test.Results:Forty-four postpartum women were included (22 from the Pregnancy and Rheumatic Diseases Clinic and 22 from the Obstetrics Department, both groups from the University Hospital “Dr. José E. González in Monterrey, México). The mean level of fear found in women with rheumatic disease was 16 (6.6) points versus 14 (4.6) points in the non-rheumatic patients group. No significant difference was found between groups (p=0.65). Regarding the rheumatic diseases group, women in the category of other diagnoses (that included Sjögren’s Syndrome, antiphospholipid syndrome, and dermatomyositis) had a greater mean FCV-19S score (20.2), than patients with systemic lupus erythematosus (17.3) and rheumatoid arthritis (15.4).Conclusion:Women with postpartum rheumatic disease had a higher FCV-19S score than postpartum women without rheumatic diseases, although this difference was not statistically significant.References:[1]Lumbreras-Marquez MI, Campos-Zamora M, Seifert SM, et al. Excess Maternal Deaths Associated With Coronavirus Disease 2019 (COVID-19) in Mexico. Obstet Gynecol. 2020;136(6):1114-1116. doi:10.1097/AOG.0000000000004140[2]Yan H, Ding Y, Guo W. Mental Health of Pregnant and Postpartum Women During the Coronavirus Disease 2019 Pandemic: A Systematic Review and Meta-Analysis. Front Psychol. 2020;11:617001. Published 2020 Nov 25. doi:10.3389/fpsyg.2020.617001Table 1.Sociodemographic dataWomen with rheumatic diseasesN= 22Women without rheumatic diseases N= 22p=Age, years, mean, (SD)28 (6.8)23 (5.0)0.65Occupation, n (%)Housewive14 (63.6)18 (81.8)Employee5 (22.7)3 (13.6)Other3 (13.6)1 (4.5)Education level, n (%)0.28Middle school10 (45.45)16 (72.72)High School8 (36.36)5 (22.72)College4 (18.18)1 (4.54)Rheumatic diagnosis, n(%)Rheumatoid arthritis9 (40.9)Systemic lupus erythematosus8 (36.6)Others (SS, APS, DM)5 (22.7)SS: Sjögren’s syndrome, APS: antiphospholipid syndrome, DM: dermatomyositisDisclosure of Interests:None declared.
48
Sattui, Sebastian Eduardo, Jean W. Liew, Kevin Kennedy, Emily Sirotich, Michael Putman, Tarin T. Moni, Akpabio Akpabio, et al. "Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey." RMD Open 7, no. 3 (September 2021): e001814. http://dx.doi.org/10.1136/rmdopen-2021-001814.
Full textAbstract:
BackgroundWe describe the early experiences of adults with systemic rheumatic disease who received the COVID-19 vaccine.MethodsFrom 2 April to 30 April 2021, we conducted an online, international survey of adults with systemic rheumatic disease who received COVID-19 vaccination. We collected patient-reported data on clinician communication, beliefs and intent about discontinuing disease-modifying antirheumatic drugs (DMARDs) around the time of vaccination, and patient-reported adverse events after vaccination.ResultsWe analysed 2860 adults with systemic rheumatic diseases who received COVID-19 vaccination (mean age 55.3 years, 86.7% female, 86.3% white). Types of COVID-19 vaccines were Pfizer-BioNTech (53.2%), Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/Johnson & Johnson (1.7%) and others (1.2%). The most common rheumatic disease was rheumatoid arthritis (42.3%), and 81.2% of respondents were on a DMARD. The majority (81.9%) reported communicating with clinicians about vaccination. Most (66.9%) were willing to temporarily discontinue DMARDs to improve vaccine efficacy, although many (44.3%) were concerned about rheumatic disease flares. After vaccination, the most reported patient-reported adverse events were fatigue/somnolence (33.4%), headache (27.7%), muscle/joint pains (22.8%) and fever/chills (19.9%). Rheumatic disease flares that required medication changes occurred in 4.6%.ConclusionAmong adults with systemic rheumatic disease who received COVID-19 vaccination, patient-reported adverse events were typical of those reported in the general population. Most patients were willing to temporarily discontinue DMARDs to improve vaccine efficacy. The relatively low frequency of rheumatic disease flare requiring medications was reassuring.
49
Peláez-Ballestas, Ingris, Ysabel Granados, Rosana Quintana, Adalberto Loyola-Sánchez, Flor Julián-Santiago, Celenia Rosillo, Alfonso Gastelum-Strozzi, et al. "Epidemiology and socioeconomic impact of the rheumatic diseases on indigenous people: an invisible syndemic public health problem." Annals of the Rheumatic Diseases 77, no. 10 (July 14, 2018): 1397–404. http://dx.doi.org/10.1136/annrheumdis-2018-213625.
Full textAbstract:
Epidemiological studies in Latin America suggest indigenous people lack proper healthcare for musculoskeletal (MSK) and rheumatic diseases.ObjectivesThis study aimed to estimate the prevalence of MSK disorders and rheumatic diseases in eight Latin American indigenous communities, and to identify which factors influence such prevalence using network analysis and syndemic approach.MethodsThis is a cross-sectional, community-based census study according to Community-Oriented Program for the Control of Rheumatic Diseases methodology. Individuals with MSK pain, stiffness or swelling in the past and/or during the last 7 days were evaluated by participating physicians. A descriptive, univariable and multivariable analysis was performed, followed by a network analysis.ResultsWe surveyed 6155 indigenous individuals with a mean age of 41.2 years (SD 17.6; range 18–105); 3757 (61.0%) were women. Point prevalence in rank order was: low back pain in 821 (13.3%); osteoarthritis in 598 (9.7%); rheumatic regional pain syndromes in 368 (5.9%); rheumatoid arthritis in 85 (1.3%); undifferentiated arthritis in 13 (0.2%); and spondyloarthritis in 12 (0.1%). There were marked variations in the prevalence of each rheumatic disease among the communities. Multivariate models and network analysis revealed a complex relationship between rheumatic diseases, comorbidities and socioeconomic conditions.ConclusionsThe overall prevalence of MSK disorders in Latin American indigenous communities was 34.5%. Although low back pain and osteoarthritis were the most prevalent rheumatic diseases, wide variations according to population groups occurred. The relationship between rheumatic diseases, comorbidities and socioeconomic conditions allows taking a syndemic approach to the study.
50
Ha, You-Jung, Yun Jong Lee, and Eun Ha Kang. "Lung Involvements in Rheumatic Diseases: Update on the Epidemiology, Pathogenesis, Clinical Features, and Treatment." BioMed Research International 2018 (2018): 1–19. http://dx.doi.org/10.1155/2018/6930297.
Full textAbstract:
Lung illness encountered in patients with rheumatic diseases bears clinical significance in terms of increased morbidity and mortality as well as potential challenges placed on patient care. Although our understanding of natural history of this important illness is still limited, epidemiologic knowledge has been accumulated during the past decade to provide useful information on the risk factors and prognosis of lung involvements in rheumatic diseases. Moreover, the pathogenesis particularly in the context of genetics has been greatly updated for both the underlying rheumatic disease and associated lung involvement. This review will focus on the current update on the epidemiologic and genetics features and treatment options of the lung involvements associated with four major rheumatic diseases (rheumatoid arthritis, systemic sclerosis, myositis, and systemic lupus erythematosus), with more attention to a specific form of involvement or interstitial lung disease.